Intervention
fluticasone propionate/salmeterol
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownA 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese SubjectsNCT01751113 · 2013-02-01
COMPLETEDInvestigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent AsthmaNCT00557440 · 2007-11-01
COMPLETEDStudy Of RV-39 In Patients Who Also Have AsthmaNCT00503009 · 2007-10-01
TERMINATEDA 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With AsthmaNCT00441441 · 2007-02-01
COMPLETEDStudy Of Patients With Allergic Rhinitis And AsthmaNCT00296530 · 2005-09-01
COMPLETEDSpacer Comparison In Adult AsthmaticsNCT00369993 · 2005-03-01
COMPLETEDRepeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In AsthmaticsNCT00364442 · 2005-01-28
COMPLETEDStudy Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol XinafoateNCT00102882 · 2004-10-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED7
TERMINATED1
Phase mix
PHASE44
PHASE22
PHASE11
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.